Maxim Group Maintains Buy on Capricor Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has maintained a Buy rating on Capricor Therapeutics and raised the price target from $12 to $25.
September 25, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group's analyst Jason McCarthy has reaffirmed a Buy rating for Capricor Therapeutics and significantly increased the price target from $12 to $25, indicating strong confidence in the company's future performance.
The analyst's decision to maintain a Buy rating and raise the price target significantly suggests a positive outlook for Capricor Therapeutics. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100